Fabio Martelli

List of Publications by Year in Descending Order

117 papers	8,544 citations	52 h-index	91 g-index
133 ext. papers	9,591 ext. citations	7.6 avg, IF	5.79 L-index

#	Paper	IF	Citations
117	Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the gene.. *Molecular Therapy - Nucleic Acids*, **2022**, 27, 184-199	10.7	1
116	Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: A Position Paper from the EU-CardioRNA COST Action CA17129. *Cardiovascular Research*, **2021**,	9.9	2
115	Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129. *Cardiovascular Research*, **2021**, 117, 1823-1840	9.9	5
114	Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia. *Cell Death and Disease*, **2021**, 12, 435	9.8	1
113	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. *Science Advances*, **2021**, 7,	14.3	7
112	Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	17
111	Regulatory RNAs in cardiovascular disease **2021**, 127-162		
110	Dissecting the transcriptome in cardiovascular disease. *Cardiovascular Research*, **2021**,	9.9	3
109	Mitochondrial-cell cycle cross-talk drives endoreplication in heart disease. *Science Translational Medicine*, **2021**, 13, eabi7964	17.5	2
108	Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis. *Cells*, **2020**, 9,	7.9	20
107	Regulatory RNAs in Heart Failure. *Circulation*, **2020**, 141, 313-328	16.7	68
106	Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
105	Call to action for the cardiovascular side of COVID-19. *European Heart Journal*, **2020**, 41, 1796-1797	9.5	9
104	Dysregulation of microRNA expression in diabetic skin. *Journal of Dermatological Science*, **2020**, 98, 186-194	4.4	4
103	The epigenetic implication in coronavirus infection and therapy. *Clinical Epigenetics*, **2020**, 12, 156	7.7	29
102	Approaching Sex Differences in Cardiovascular Non-Coding RNA Research. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
101	Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era. *Journal of Translational Medicine*, **2020**, 18, 408	8.5	11

100	Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
99	Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome. *Journal of Clinical Medicine*, **2020**, 9,	5.1	36
98	The Dark That Matters: Long Non-coding RNAs as Master Regulators of Cellular Metabolism in Non-communicable Diseases. *Frontiers in Physiology*, **2019**, 10, 369	4.6	42
97	Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	18
96	Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. *Non-coding RNA*, **2019**, 5,	7.1	7
95	Long Noncoding Competing Endogenous RNA Networks in Age-Associated Cardiovascular Diseases. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	30
94	Hypoxia-Induced miR-210 Is Necessary for Vascular Regeneration upon Acute Limb Ischemia. *International Journal of Molecular Sciences*, **2019**, 21,	6.3	12
93	P300/CBP-associated factor regulates transcription and function of isocitrate dehydrogenase 2 during muscle differentiation. *FASEB Journal*, **2019**, 33, 4107-4123	0.9	10
92	Noncoding RNAs in the Vascular System Response to Oxidative Stress. *Antioxidants and Redox Signaling*, **2019**, 30, 992-1010	8.4	23
91	Zeb1-Hdac2-eNOS circuitry identifies early cardiovascular precursors in naive mouse embryonic stem cells. *Nature Communications*, **2018**, 9, 1281	17.4	10
90	Long Noncoding RNAs and Cardiac Disease. *Antioxidants and Redox Signaling*, **2018**, 29, 880-901	8.4	38
89	High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2. *Cell Death and Disease*, **2018**, 9, 729	9.8	11
88	miR-210 Enhances the Therapeutic Potential of Bone-Marrow-Derived Circulating Proangiogenic Cells in the Setting of Limb Ischemia. *Molecular Therapy*, **2018**, 26, 1694-1705	11.7	18
87	Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells From Type2 Diabetes Patients: Rescue by □Ketoglutarate and TET-TDG Functional Reactivation. *Circulation Research*, **2018**, 122, 31-46	15.7	23
86	Circular RNAs in Muscle Function and Disease. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	52
85	Circular RNAs: Methodological challenges and perspectives in cardiovascular diseases. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 5176-5187	5.6	45
84	Increased BACE1-AS long noncoding RNA and □amyloid levels in heart failure. *Cardiovascular Research*, **2017**, 113, 453-463	9.9	51
83	Oxidative Stress-Induced miR-200c Disrupts the Regulatory Loop Among SIRT1, FOXO1, and eNOS. *Antioxidants and Redox Signaling*, **2017**, 27, 328-344	8.4	90

82	Overexpression of miR-210 and its significance in ischemic tissue damage. *Scientific Reports*, **2017**, 7, 9563	4.9	28
81	Age-dependent increase of oxidative stress regulates microRNA-29 family preserving cardiac health. *Scientific Reports*, **2017**, 7, 16839	4.9	34
80	CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients. *Molecular Therapy - Nucleic Acids*, **2017**, 9, 337-348	10.7	44
79	The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration. *Pharmacology & Therapeutics*, **2017**, 171, 43-55	13.9	9
78	The expression of the BPIFB4 and CXCR4 associates with sustained health in long-living individuals from Cilento-Italy. *Aging*, **2017**, 9, 370-380	5.6	23
77	Central role of the p53 pathway in the noncoding-RNA response to oxidative stress. *Aging*, **2017**, 9, 2559-2586	5.6	39
76	Long noncoding RNA dysregulation in ischemic heart failure. *Journal of Translational Medicine*, **2016**, 14, 183	8.5	138
75	MicroRNA-222 regulates muscle alternative splicing through Rbm24 during differentiation of skeletal muscle cells. *Cell Death and Disease*, **2016**, 7, e2086	9.8	36
74	Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. *Scientific Reports*, **2016**, 6, 38174	4.9	36
73	Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing. *Scientific Reports*, **2016**, 6, 24141	4.9	95
72	microRNAs in ischaemic cardiovascular diseases. *European Heart Journal Supplements*, **2016**, 18, E31-E36	1.5	8
71	Proliferation of Multiple Cell Types in the Skeletal Muscle Tissue Elicited by Acute p21 Suppression. *Molecular Therapy*, **2015**, 23, 885-895	11.7	5
70	Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. *Cancer Research*, **2015**, 75, 3771-87	10.1	84
69	p75(NTR)-dependent activation of NF-B regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia. *Nature Communications*, **2015**, 6, 8024	17.4	89
68	Noncoding RNA in age-related cardiovascular diseases. *Journal of Molecular and Cellular Cardiology*, **2015**, 83, 142-55	5.8	87
67	Sirtuin function in aging heart and vessels. *Journal of Molecular and Cellular Cardiology*, **2015**, 83, 55-61	5.8	67
66	Magnetic Resonance Imaging Allows the Evaluation of Tissue Damage and Regeneration in a Mouse Model of Critical Limb Ischemia. *PLoS ONE*, **2015**, 10, e0142111	3.7	23
65	Emerging Roles of Non-Coding RNAs in the Hypoxic Response. *Cancer Drug Discovery and Development*, **2014**, 43-64	0.3	2

64	MiR-216a: a link between endothelial dysfunction and autophagy. *Cell Death and Disease*, **2014**, 5, e1029	9.8	104
63	HypoxamiR regulation and function in ischemic cardiovascular diseases. *Antioxidants and Redox Signaling*, **2014**, 21, 1202-19	8.4	55
62	Epigenetic mechanisms of hyperglycemic memory. *International Journal of Biochemistry and Cell Biology*, **2014**, 51, 155-8	5.6	33
61	Plasma microRNAs as biomarkers for myotonic dystrophy type 1. *Neuromuscular Disorders*, **2014**, 24, 509-15	2.9	50
60	The histone acetylase activator pentadecylidenemalonate 1b rescues proliferation and differentiation in the human cardiac mesenchymal cells of type 2 diabetic patients. *Diabetes*, **2014**, 63, 2132-47	0.9	57
59	Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2. *PLoS ONE*, **2014**, 9, e93983	3.7	19
58	Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction. *BioMed Research International*, **2014**, 2014, 193095	3	57
57	Noncoding RNAs: emerging players in muscular dystrophies. *BioMed Research International*, **2014**, 2014, 503634	3	14
56	Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia. *Antioxidants and Redox Signaling*, **2014**, 21, 1177-88	8.4	42
55	Oxidative stress and epigenetic regulation in ageing and age-related diseases. *International Journal of Molecular Sciences*, **2013**, 14, 17643-63	6.3	162
54	Transcriptional profiling of HMGB1-induced myocardial repair identifies a key role for Notch signaling. *Molecular Therapy*, **2013**, 21, 1841-51	11.7	21
53	Oxidative stress and microRNAs in vascular diseases. *International Journal of Molecular Sciences*, **2013**, 14, 17319-46	6.3	140
52	A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair. *Journal of Biological Chemistry*, **2013**, 288, 11004-12	5.4	58
51	Enhancement of lysine acetylation accelerates wound repair. *Communicative and Integrative Biology* , **2013**, 6, e25466	1.7	29
50	MicroRNAs and Tissue Response to Acute Ischemia. *Contributions To Statistics*, **2013**, 97-112	0.1	
49	Hypoxia-inducible factor 1-induces miR-210 in normoxic differentiating myoblasts. *Journal of Biological Chemistry*, **2012**, 287, 44761-71	5.4	71
48	MicroRNA dysregulation in diabetic ischemic heart failure patients. *Diabetes*, **2012**, 61, 1633-41	0.9	168
47	ROD1 is a seedless target gene of hypoxia-induced miR-210. *PLoS ONE*, **2012**, 7, e44651	3.7	33

46	Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. *Rna*, **2012**, 18, 472-84	5.8	107
45	Deregulated microRNAs in myotonic dystrophy type 2. *PLoS ONE*, **2012**, 7, e39732	3.7	71
44	Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. *Neuromuscular Disorders*, **2011**, 21, 81-8	2.9	90
43	MicroRNA-155 targets the SKI gene in human melanoma cell lines. *Pigment Cell and Melanoma Research*, **2011**, 24, 538-50	4.5	66
42	miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. *Cell Death and Differentiation*, **2011**, 18, 1628-39	12.7	352
41	microRNAs as peripheral blood biomarkers of cardiovascular disease. *Vascular Pharmacology*, **2011**, 55, 111-8	5.9	57
40	miR-210: More than a silent player in hypoxia. *IUBMB Life*, **2011**, 63, 94-100	4.7	147
39	Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. *Circulation*, **2011**, 123, 282-91	16.7	322
38	Knockdown of cyclin-dependent kinase inhibitors induces cardiomyocyte re-entry in the cell cycle. *Journal of Biological Chemistry*, **2011**, 286, 8644-8654	5.4	60
37	Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation. *Cancer Research*, **2010**, 70, 9711-20	10.1	34
36	MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. *Circulation*, **2010**, 122, S124-31	16.7	355
35	Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. *Cardiovascular Research*, **2010**, 85, 272-80	9.9	30
34	Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. *European Heart Journal*, **2010**, 31, 2765-73	9.5	618
33	MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. *Physiological Genomics*, **2010**, 42, 420-6	3.6	106
32	microRNA: emerging therapeutic targets in acute ischemic diseases. *Pharmacology & Therapeutics*, **2010**, 125, 92-104	13.9	147
31	p66ShcA modulates oxidative stress and survival of endothelial progenitor cells in response to high glucose. *Cardiovascular Research*, **2009**, 82, 421-9	9.9	54
30	An integrated approach for experimental target identification of hypoxia-induced miR-210. *Journal of Biological Chemistry*, **2009**, 284, 35134-43	5.4	215
29	Correction for Colussi et al., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 1679-1679	11.5	78

28	Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. *FASEB Journal*, **2009**, 23, 3335-46	0.9	207
27	Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. *Neoplasia*, **2009**, 11, 732-42	6.4	29
26	Microrna-221 and microrna-222 modulate differentiation and maturation of skeletal muscle cells. *PLoS ONE*, **2009**, 4, e7607	3.7	165
25	Hypoxia response and microRNAs: no longer two separate worlds. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 1426-31	5.6	170
24	HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19183-7	11.5	212
23	Protein phosphatase 2A subunit PR70 interacts with pRb and mediates its dephosphorylation. *Molecular and Cellular Biology*, **2008**, 28, 873-82	4.8	52
22	MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. *Journal of Biological Chemistry*, **2008**, 283, 15878-83	5.4	673
21	Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. *Circulation Research*, **2008**, 102, 51-8	15.7	106
20	p66(ShcA) and oxidative stress modulate myogenic differentiation and skeletal muscle regeneration after hind limb ischemia. *Journal of Biological Chemistry*, **2007**, 282, 31453-9	5.4	62
19	Molecular mechanisms of cardiomyocyte regeneration and therapeutic outlook. *Trends in Molecular Medicine*, **2007**, 13, 125-33	11.5	12
18	Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. *Cardiovascular Research*, **2006**, 70, 578-88	9.9	7
17	Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 11015-20	11.5	88
16	Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress. *FASEB Journal*, **2006** , 20, 1242-4	0.9	38
15	Impaired T- and B-cell development in Tcl1-deficient mice. *Blood*, **2005**, 105, 1288-94	2.2	31
14	p66ShcA modulates tissue response to hindlimb ischemia. *Circulation*, **2004**, 109, 2917-23	16.7	103
13	Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation. *Journal of Biological Chemistry*, **2004**, 279, 16332-8	5.4	96
12	Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. *Circulation*, **2004**, 110, 3341-8	16.7	46
11	p21(Waf1/Cip1/Sdi1) mediates shear stress-dependent antiapoptotic function. *Cardiovascular Research*, **2004**, 61, 693-704	9.9	16

10	Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. *Journal of Biological Chemistry*, **2003**, 278, 19509-17	5.4	90
9	Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. *Molecular Cell*, **2003**, 12, 735-46	17.6	101
8	MyoD stimulates RB promoter activity via the CREB/p300 nuclear transduction pathway. *Molecular and Cellular Biology*, **2003**, 23, 2893-906	4.8	66
7	p19ARF targets certain E2F species for degradation. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 4455-60	11.5	159
6	Regulation of endogenous E2F1 stability by the retinoblastoma family proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 2858-63	11.5	32
5	The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. *Genes and Development*, **1996**, 10, 2949-59	12.6	192
4	Characterization of two novel YY1 binding sites in the polyomavirus late promoter. *Journal of Virology*, **1996**, 70, 1433-8	6.6	9
3	MyoD induces retinoblastoma gene expression during myogenic differentiation. *Oncogene*, **1994**, 9, 3579-90	9.2	81
2	Regulation of MyoD gene transcription and protein function by the transforming domains of the adenovirus E1A oncoprotein. *Oncogene*, **1993**, 8, 267-78	9.2	70
1	EVIDENCE FOR BIOLOGICAL AGE ACCELERATION AND TELOMERE SHORTENING IN COVID19 SURVIVORS		5